特发性亚临床甲状腺功能减退症儿童的认知功能:2年左甲状腺素治疗的影响
该前瞻性病例对照研究纳入34例长期特发性轻度亚临床甲状腺功能减退症(SH)儿童和34名健康匹配对照,其中20例SH儿童接受2年左甲状腺素(L-T4)治疗(A组),14例拒绝治疗并随访2年(B组)。SH儿童基线智商正常且与对照相当;A组L-T4治疗使促甲状腺激素正常化,但2年L-T4治疗未伴随智商评分变化,A组与B组随访2年后智商评分无显著差异。
要点
- SH儿童基线全量表智商、言语智商和操作智商均正常且与健康对照相当。
- A组L-T4治疗2年使促甲状腺激素从基线6.3±1.0 mIU/L降至2.8±1.4 mIU/L(P<.001)。
- 2年L-T4治疗未伴随智商评分变化,A组与B组随访2年后智商评分无显著差异。
核心结论
- 数据提示儿童持续性轻度未治疗的SH不损害神经认知功能,且2年L-T4补充未显著改变神经认知功能。
研究设计与样本
- 2年病例对照前瞻性研究,纳入34例年龄9.1±2.6岁的长期特发性轻度SH儿童和34名健康匹配对照。
- 20例SH儿童接受2年L-T4治疗(A组),14例拒绝治疗并在2年随访后重新评估(B组)。
- 所有儿童在研究入组时评估智商和特定认知域,SH个体在2年治疗(A组)或观察(B组)后再次评估。
主要发现
- SH儿童基线智商评分正常且与对照相当:全量表智商100.4±11.3 vs 101.8±14.2,言语智商99.7±13.7 vs 98.3±14.9,操作智商101.2±10.4 vs 105±10.4。
- A组L-T4治疗伴随促甲状腺激素正常化:基线6.3±1.0 mIU/L vs 2年2.8±1.4 mIU/L,P<.001。
- 2年L-T4治疗未伴随智商评分变化:全量表智商104.4±13.8 vs 102.7±11.0,言语智商101.8±14.9 vs 102.3±11.9,操作智商106.5±13.9 vs 102.7±10.7。
- 2年L-T4治疗未伴随言语或操作分测验评分变化。
- A组治疗2年后与B组随访2年后智商评分无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term consequences of mild subclinical hypothyroidism (SH) in children are still unclear, and the need for levothyroxine (L-T4) supplementation remains controversial. We designed a 2-year, case-control, prospective study of a cohort of children with SH to evaluate the effects of L-T4 therapy on neurocognitive outcome. METHODS: Thirty-four children, age 9.1 ± 2.6 years, with long-lasting, idiopathic, and mild SH, and 34 healthy matched controls, were enrolled. Twenty SH children underwent a 2-year L-T4 treatment (group A), whereas 14 refused treatment and were reevaluated after a 2-year-follow-up (group B). IQ and specific cognitive domains were evaluated in all children at study entry and after 2 years of therapy (group A) or observation (group B) in SH individuals. RESULTS: In SH children baseline IQ scores were normal and comparable to controls (full-scale IQ [FSIQ] 100.4 ± 11.3 vs 101.8 ± 14.2, verbal IQ [VIQ] 99.7 ± 13.7 vs 98.3 ± 14.9 and performance IQ [PIQ] 101.2 ± 10.4 vs 105 ± 10.4).In group A, L-T4 treatment was associated with normalization of thyrotropin (6.3 ± 1.0 mIU/L at baseline vs 2.8 ± 1.4 mIU/L at 2 years, P < .001). However, 2-year L-T4 therapy was not associated with a change in IQ scores (FSIQ 104.4 ± 13.8 vs 102.7 ± 11.0; VIQ 101.8 ± 14.9 vs 102.3 ± 11.9; and PIQ 106.5 ± 13.9 vs 102.7 ± 10.7) or in verbal or performance subtest scores. No significant differences were found in IQ scores after 2 years of treatment in group A compared to group B after a 2-year follow-up. CONCLUSIONS: Our data suggest neurocognitive function in children is not impaired by persistent, mild, untreated SH and is not significantly modified by 2-year L-T4 supplementation.
引用
- Capalbo D, Alfano S, Polizzi M, et al. Cognitive Function in Children With Idiopathic Subclinical Hypothyroidism: Effects of 2 Years of Levothyroxine Therapy. J Clin Endocrinol Metab. 2020. PMID: 32002552. doi:10.1210/clinem/dgaa046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。